Table 1

Baseline characteristics of participants included in this evaluation

Control group
n=65
rtCGM group
n=70
Age (years)47.1±10.145.7±11.7
Women20 (31%)31 (44%)
Men45 (69%)39 (56%)
Diabetes duration (years)21.0±13.120.9±14.1
BMI (kg/m2)26.1±4.726.2±6.7
HbA1c (% (mmol/mol))7.4±1.0 (57±10)7.5±1.0 (58±10)
Severe hypoglycemia in the last 12 months41 (63%)45 (64%)
Hypoglycemia unawareness59 (91%)66 (94%)
Basal insulin
 Insulin degludec8 (12%)5 (7%)
 Insulin detemir22 (34%)24 (34%)
 Insulin glargine30 (46%)35 (50%)
 NPH insulin2 (3%)4 (6%)
 More than one1 (2%)1 (1%)
 Not known2 (3%)1 (1%)
Bolus insulin
 Insulin aspart24 (37%)31 (44%)
 Insulin glulisine8 (12%)6 (9%)
 Insulin lispro26 (40%)23 (33%)
 Regular insulin5 (8%)7 (10%)
 More than one1 (2%)2 (3%)
 Not known1 (2%)1 (1%)
  • Data are mean±SD or total number and percentages.

  • BMI, body mass index; NPH, neutral protamine Hagedorn; rtCGM, real-time continuous glucose monitoring.